Clinical Effects of Dipyridamole (Persantin®) on Nephrotic Syndrome

DOI Web Site PubMed
  • UEDA Yasushi
    Tokyo Jikei University School of Medicine, Second Internal Medicine
  • TOJO Shizuo
    Institute of Clinical Medicine, The University of Tsukuba
  • HATANO Michinobu
    The 2 nd Department of Internal Medicine, Nihon University School of Medicine
  • FURUKAWA Toshiyuki
    Institute of Medical Electronics, Faculty of Medicine, University of Tokyo
  • YOSHINAGA Kaoru
    The 2 nd Department o f Internal Medicine, T ohoku University School o f Medicine
  • KINOSHITA Yasutami
    Second Department of Internal Medicine, Niigata University School of Medicine
  • TAKEUCHI Jugoro
    Second Department of Internal Medicine, Tokyo Medical and Dental University
  • KATO Eiichi
    Department of Internal Medicine, School of Medicine, Keio University
  • OHNO Joji
    Department of Internal Medicine, Devision of Nephrology, Juntendo University, School of Medicine
  • KOBAYASHI Kaizo
    Department of Internal Medicine, Nagoya University Branch Hospital
  • ABE Hiroshi
    The 1st Department of Medicine, Osaka University Medical School
  • OMAE Seruo
    The 2 nd Department of Internal Medicine, Kyushu University

Bibliographic Information

Other Title
  • ネフローゼ症候群におけるDipyridamole (Persantin®)の臨床効果
  • ネフローゼ ショウコウグン ニ オケル Dipyridamole Persan
  • Multiclinic Double Blind Test
  • ―多施設二重盲検試験―

Search this article

Description

Dipyridamole (Persantin) 300 mg/day, or its placebo were administered for 4 weeks to the nephrotic syndrome who had been treated by corticosteroids and their effects were compared by double blind method. 1) General improvement rate of Persantin (88.2%) was significantly (p<0.05) higher than that of placebo (46.7%) in steroid unresponsive nephrotic syndrome group. 2) As to urinary protein decreasing effect indicated by average decreasing rates of urinary protein in a week, the effect was better in Persantin group than in placebo group in the 1st and 2nd week. The same results were confirmed more evidently in the steroid unresponsive nephrotic syndrome group and also in those patient except minimal changes in histological classification. 3) As to the endogenous creatinine clearance, Persantin group showed a significantly large increase, compared with placebo group. 4) As to serum cholesterol level and triglycerid level, Persantin group showed a bigger tende-ncy to decrease, compared with placebo group. 5) As for side effects, headache, palpitation, nausea, retching, and others were observed in Persantin group. However, these were not serious and disappeared after discontinuation of administra-tion of the drug.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top